Evidence map›Paper›PMID 38985413›Full record

ArticleIndian journal of gastroenterology : official journal of the Indian Society of Gastroenterology2024

Characteristics and survival of advanced untreated hepatocellular carcinoma of non-viral etiology.

Senarath Pathiranage Nimasha Ekanayaka, Nathasha Luke, Suchintha Bandara Thilakarathne, Anuradha Dassanayake, Mahiman Bhaagya Gunetilleke, Madunil A Niriella, Rohan Chaminda Siriwardana

Abstract read
PubMed Publisher
In one paragraph

Article in Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Senarath Pathiranage Nimasha EkanayakaDepartment of Surgery, Faculty of Medicine, Colombo North Center for Liver Disease, University of Kelaniya, Thalagolla Road, Ragama, Sri Lanka.
Nathasha LukeDepartment of Pharmacology, Faculty of Medicine, Colombo North Center for Liver Disease, University of Kelaniya, Ragama, Sri Lanka.
Suchintha Bandara ThilakarathneDepartment of Surgery, Faculty of Medicine, Colombo North Center for Liver Disease, University of Kelaniya, Thalagolla Road, Ragama, Sri Lanka.ORCID 0000-0002-6499-4644
Anuradha DassanayakeDepartment of Pharmacology, Faculty of Medicine, Colombo North Center for Liver Disease, University of Kelaniya, Ragama, Sri Lanka.
Mahiman Bhaagya GunetillekeDepartment of Surgery, Faculty of Medicine, Colombo North Center for Liver Disease, University of Kelaniya, Thalagolla Road, Ragama, Sri Lanka.
Madunil A NiriellaDepartment of Surgery, Faculty of Medicine, Colombo North Center for Liver Disease, University of Kelaniya, Thalagolla Road, Ragama, Sri Lanka.
Rohan Chaminda SiriwardanaDepartment of Surgery, Faculty of Medicine, Colombo North Center for Liver Disease, University of Kelaniya, Thalagolla Road, Ragama, Sri Lanka. rohansiriwardana@yahoo.com.ORCID 0000-0002-6477-2072

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

INTRODUCTION AND

objectivesHepatocellular carcinoma (HCC) is an aggressive tumor and presents late. The underlying etiology of HCC is changing rapidly. HCC in Sri Lanka is unique due to its predominant non-viral etiology (nvHCC) but lacks survival data.

methodData was collected from patients who presented with HCC from 2011 to 2018. There were 560/568 (98.6%) nvHCC. The patients who were not candidates for tumor-specific treatment (149/560 [26.7%]) were selected. Population characteristics, demographic data, tumor characteristics, survival and factors affecting survival were analyzed.

resultsThe median age was 64 years (range 30-88) and 86% (n = 129) were males. As many as 124 (83%) were cirrhotic. The overall performance score was 80%. Nearly 21/124 tumors were detected in cirrhotic screening. Tumors were single nodular in 32 (21%), up to three nodules in 28 (18%), more than three nodules in 33 (22%) and diffusely infiltrating in 56 (37%). The major venous invasions were present in 78 (52.3%). Extra-hepatic tumor spread was seen in 19 (12.7%) (lungs 13 [72.2%], bones 2 [11.1%]). The median survival of patients receiving palliative care was three months (1-43 months). Tumor size and cirrhotic status were significant predictors in univariate analysis.

conclusionA quarter of nvHCCs were not amenable to treatment at presentation as they had dismal survival. CLINICAL TRIAL REGISTRY NUMBER: P/126/09/2021.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsAdultAgedAged, 80 and overFemaleHumansLiver CirrhosisMaleMiddle AgedSri LankaSurvival RateEpidemiologyHepatocellular carcinomaLiver neoplasmsPalliative careSurvival

Identifiers

PMID38985413

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.